Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John Ashcroft

Showing results (11-20 of 34) with videos related to

Pageof 4
Sort By:
British Journal of Haematology|September 9, 2024
Advanced imaging for earlier diagnosis and morbidity prevention in multiple myeloma: A British Society of Haematology and UK Myeloma Society Good Practice PaperMartin Kaiser, Vicky Goh, Simon Stern, et al.
British Journal of Haematology|April 27, 2011
Guidelines for supportive care in multiple myeloma 2011John A Snowden, Sam H Ahmedzai, John Ashcroft, et al.
Blood Cancer Journal|March 16, 2023
Delayed diagnosis resulting in increased disease burden in multiple myeloma: the legacy of the COVID-19 pandemicJonathan Carmichael, Frances Seymour, Graham McIlroy, et al.
British Journal of Haematology|February 16, 2008
IgM myeloma: a rare entity characterized by a CD20-CD56-CD117- immunophenotype and the t(11;14)Sylvia Feyler, Sheila J M O'Connor, Andy C Rawstron, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 23, 2011
A gene expression-based predictor for myeloma patients at high risk of developing bone disease on bisphosphonate treatmentPing Wu, Brian A Walker, Daniel Brewer, et al.
Blood|October 18, 2002
Flow cytometric disease monitoring in multiple myeloma: the relationship between normal and neoplastic plasma cells predicts outcome after transplantationAndy C Rawstron, Faith E Davies, Ranjit DasGupta, et al.
British Journal of Haematology|January 8, 2025
Diagnosis and management of monoclonal gammopathy of renal significance: A British Society for Haematology good practice paperJennifer Pinney, Candice Roufosse, Andreas Kousios, et al.
Blood|April 14, 2012
Effects of induction and maintenance plus long-term bisphosphonates on bone disease in patients with multiple myeloma: the Medical Research Council Myeloma IX TrialGareth J Morgan, Faith E Davies, Walter M Gregory, et al.
Bone Marrow Transplantation|June 29, 2022
Association of genetic variants with patient reported quality of life and pain experience in patients in the UK NCRI Myeloma X Relapse [Intensive]) trial; an exploratory studyJohn A Snowden, Sam H Ahmedzai, Angela Cox, et al.
Blood|June 7, 2003
Polymorphic variation in GSTP1 modulates outcome following therapy for multiple myelomaRanjit K Dasgupta, Peter J Adamson, Faith E Davies, et al.
Pageof 4

Showing results (11-20 of 34) with videos related to

Sort By:
Pageof 4
British Journal of Haematology|September 9, 2024
Advanced imaging for earlier diagnosis and morbidity prevention in multiple myeloma: A British Society of Haematology and UK Myeloma Society Good Practice PaperMartin Kaiser, Vicky Goh, Simon Stern, et al.
British Journal of Haematology|April 27, 2011
Guidelines for supportive care in multiple myeloma 2011John A Snowden, Sam H Ahmedzai, John Ashcroft, et al.
Blood Cancer Journal|March 16, 2023
Delayed diagnosis resulting in increased disease burden in multiple myeloma: the legacy of the COVID-19 pandemicJonathan Carmichael, Frances Seymour, Graham McIlroy, et al.
British Journal of Haematology|February 16, 2008
IgM myeloma: a rare entity characterized by a CD20-CD56-CD117- immunophenotype and the t(11;14)Sylvia Feyler, Sheila J M O'Connor, Andy C Rawstron, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 23, 2011
A gene expression-based predictor for myeloma patients at high risk of developing bone disease on bisphosphonate treatmentPing Wu, Brian A Walker, Daniel Brewer, et al.
Blood|October 18, 2002
Flow cytometric disease monitoring in multiple myeloma: the relationship between normal and neoplastic plasma cells predicts outcome after transplantationAndy C Rawstron, Faith E Davies, Ranjit DasGupta, et al.
British Journal of Haematology|January 8, 2025
Diagnosis and management of monoclonal gammopathy of renal significance: A British Society for Haematology good practice paperJennifer Pinney, Candice Roufosse, Andreas Kousios, et al.
Blood|April 14, 2012
Effects of induction and maintenance plus long-term bisphosphonates on bone disease in patients with multiple myeloma: the Medical Research Council Myeloma IX TrialGareth J Morgan, Faith E Davies, Walter M Gregory, et al.
Bone Marrow Transplantation|June 29, 2022
Association of genetic variants with patient reported quality of life and pain experience in patients in the UK NCRI Myeloma X Relapse [Intensive]) trial; an exploratory studyJohn A Snowden, Sam H Ahmedzai, Angela Cox, et al.
Blood|June 7, 2003
Polymorphic variation in GSTP1 modulates outcome following therapy for multiple myelomaRanjit K Dasgupta, Peter J Adamson, Faith E Davies, et al.
Pageof 4